Retatrutide: what the published research shows

Retatrutide, also known by the development code LY3437943, is an investigational triple receptor agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors [1][3]. The published literature describes it as a single molecule being studied for chronic weight management, obesity and type 2 diabetes mellitus, and it has no established role in type 1 diabetes mellitus [1][3]. The evidence block used for this page does not supply a sequence, molecular formula or molecular weight for the compound, so none is stated here.

The work centres on the incretin and glucagon receptor families — GIP, GLP-1 and glucagon — and on the metabolic, hepatic, renal and cardiovascular endpoints that have been measured in preclinical models and in registered clinical studies of the compound [1][2][3][4].

Research Studies

Retatrutide and triple GIP/GLP-1/glucagon receptor agonism

Retatrutide is described in the published record as a novel triple agonist of the GIP, GLP-1 and glucagon receptors, under investigation for obesity and type 2 diabetes mellitus [1]. A separate registry entry describes the same molecule, LY3437943, as an investigational GLP-1/GIP/glucagon triple receptor agonist being studied for chronic weight management [3]. The three-receptor description is the common framing across the sources used here.

Retatrutide and diet-induced obese MASH mouse and hamster models

In diet-induced obese MASH mouse and hamster models, retatrutide was evaluated for efficacy as a triple glucagon, GIP and GLP-1 receptor agonist [4]. In mice, retatrutide strongly reduced body weight by 31% (p < 0.0001 vs. vehicle), reduced both fat and lean mass, and reduced food and water intake during the first days of treatment, while energy expenditure was not altered significantly [4]. The same report states that retatrutide markedly reduced the HOMA-IR index of insulin resistance, hepatic steatosis score, fatty acids, triglycerides and total cholesterol content [4]. In hamsters, the report states that retatrutide altered parameters that the evidence block does not enumerate, so no hamster values are given here [4].

Retatrutide and renal fibrosis in UUO and aged mice

A comparative study evaluated semaglutide, tirzepatide and retatrutide for anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis, using HK-2 cells and murine unilateral ureteral obstruction (UUO) and aging models [2]. Integrating in vivo and in vitro data showed model- and drug-specific patterns of action among the three agents [2]. In the UUO model, semaglutide effects were associated with PI3K-AKT inhibition, tirzepatide effects with PI3K-AKT inhibition and PPAR pathway activation, and retatrutide effects with concurrent inhibition of both PI3K-AKT and NF-κB pathways [2]. The evidence block truncates the description of the aging model, so no aging-model findings are reported here [2].

Retatrutide and hypoglycemia recovery in type 2 diabetes mellitus

A registered study is designed to measure the effect of retatrutide versus placebo, administered every week, on time to recovery from hypoglycemia during a hypoglycemic clamp in participants with type 2 diabetes mellitus following 16 weeks of treatment [7]. This is a study design entry; the evidence block does not report results.

Retatrutide and insulin secretion and insulin sensitivity in type 2 diabetes mellitus

A separate registered study lists as its primary objective the comparison of the effect of retatrutide and placebo on total clamp disposition index (cDI) after 28 weeks of treatment in adult participants with type 2 diabetes mellitus [8]. As above, this is a design entry and no outcome data are provided in the evidence block.

Retatrutide and dose escalation in obesity or overweight without type 2 diabetes

One registered study is intended to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight, with participation lasting about 113 weeks [5]. Another registered study is intended to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction, with participation lasting about 65 weeks and possibly including about 18 visits [6]. Both are design entries; the evidence block reports no results from either.

Retatrutide and pre-approval expanded access in severe obesity

A pre-approval single-patient expanded access entry describes provision of retatrutide (LY3437943) for adults with severe obesity, defined there as a body mass index greater than or equal to 35 kg/m² with at least two serious or life-threatening obesity-related complications, who are refractory to the best approved therapy and are unable to participate in an ongoing clinical trial of retatrutide or a comparable investigational medicine [3]. This is an access-programme description, not an efficacy report.

Retatrutide and cardiovascular risk biomarkers in adults with obesity, with or without type 2 diabetes

A post hoc analysis of phase 2 trials assessed lipoprotein and inflammatory biomarkers in adults with obesity or overweight, with or without type 2 diabetes, in order to further characterise the effects of retatrutide on cardiometabolic risk [10]. The evidence block truncates the methods description, so the specific biomarker results are not reported here [10].

Retatrutide and online-sourced product use in type 1 diabetes

A case report describes a man in his mid-30s with longstanding type 1 diabetes mellitus who developed complicating impending diabetic ketoacidosis in the context of concurrent Shigella gastroenteritis, in a setting of online-sourced retatrutide use [1]. The report notes that growing public interest in incretin-based therapies for weight loss has been accompanied by increasing availability of research peptides purchasable online, that such products may be used without medical assessment or counselling regarding adverse effects, sick-day management or appropriate follow-up, and that composition, purity and dosing accuracy may be uncertain [1]. The same report states that retatrutide has no established role in type 1 diabetes mellitus [1].

Retatrutide and product composition and labelling accuracy

A study examined the composition and labelling accuracy of products sold as retatrutide in Australia [9]. The evidence block does not enumerate the findings, so no specific values or conclusions from that study are stated here [9].

Retatrutide and diabetic rat cognition

A study examined retatrutide effects on cognition in diabetic rats [12]. The evidence block does not enumerate the findings, so no specific results are stated here [12].

Retatrutide and public reporting on access

A news item reports that the obesity drug retatrutide opened to "compassionate use" in the US after speculation that a public figure took it [11]. The evidence block does not enumerate further findings, so no additional detail is stated here [11].

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis — https://europepmc.org/article/PMC/PMC13525912
• [2] Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice — https://europepmc.org/article/PMC/PMC13495082
• [3] Pre-approval Expanded Access of Retatrutide (LY3437943) — https://clinicaltrials.gov/study/NCT07629401
• [4] Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models — https://europepmc.org/article/PMC/PMC13250738
• [5] A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight — https://clinicaltrials.gov/study/NCT07357415
• [6] A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight — https://clinicaltrials.gov/study/NCT07232719
• [7] A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia — https://clinicaltrials.gov/study/NCT06982846
• [8] A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus — https://clinicaltrials.gov/study/NCT06982859
• [9] Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia — https://europepmc.org/article/PMC/PMC13445994
• [10] Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes — https://pubmed.ncbi.nlm.nih.gov/42608321/
• [11] Retatrutide: Obesity drug opens to "compassionate use" in US after speculation Trump took it — https://pubmed.ncbi.nlm.nih.gov/42567543/
• [12] Retatrutide effects on diabetic rats' cognition — https://pubmed.ncbi.nlm.nih.gov/42527705/